关于“医药检测”的报告
艾媒咨询 | 2024年中国母婴市场发展状况与消费者调研报告
受三孩政策驱动，中国生育率有望得到提升，政策及相关配套措施落地将带动母婴消费新增量。全球新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2024年中国母婴市场发展状况与消费者调研报告》数据显示，中国母婴行业市场规模逐年稳步增长，2023年达66478亿元，预计2027年将达到89149亿元，呈现显著的上升趋势。
Driven by the three-child policy, China's fertility rate is expected to be increased, and the landing of policies and related supporting measures will drive new increases in maternal and infant market. According to the latest "China Maternal and Infant Market Development and Consumer Research Report in 2024" released by iiMedia Research, a third-party data mining and analysis institution in the global new economy industry, the market size of China's maternal and infant industry has grown steadily year by year, reaching 6,647.8 billion yuan in 2023. It is expected to reach 8914.9 billion yuan in 2027, showing a significant upward trend.-
-
-
-
艾媒咨询｜2022年中国幽门螺旋杆菌检测市场专题调查报告
美国将幽门螺杆菌被列为明确致癌物后，幽门螺杆菌在中国受到了极大的关注。iiMedia Research（艾媒咨询）数据显示，2021年中国幽门螺杆菌检测市场规模73.1亿元，预计2022年将达到86.6亿元。艾媒咨询分析师认为，随着大众的健康意识逐渐加强，幽门螺杆菌自测产品将成为必需品，幽门螺杆菌检测市场发展空间广阔。而幽门螺杆菌自测产品的上市，有助于推动居家检测。(《艾媒咨询｜2022年中国幽门螺旋杆菌检测市场专题调查报告》完整高清PDF版共23页，可点击文章底部报告下载按钮进行报告下载)
After the United States Department of Health & Human Services listed Helicobacter pylori as a definitive carcinogen, Helicobacter pylori received great attention in China. According to data from iiMedia Research, the market size of Helicobacter pylori testing in China will be 7.31 billion yuan in 2021 and is expected to reach 8.66 billion yuan in 2022. With increasing health awareness, Helicobacter pylori self-test product is necessary for people. The market for Helicobacter pylori self-test product is vast. The launch of Helicobacter pylori self-test products helps to promote home testing.（“iiMedia Report ｜Investigation Report on The Market of Helicobacter Pylori Testing in China in 2022”full version has 23 pages, please click the Browse HD Report button on the right side of the article to browse the report） -
-
-
-
-
艾媒咨询|2021年中国夜间用药年度观察报告
本报告涉及的案例/品牌/企业：美团买药，叮当快药
在众多社会服务中，夜间用药成为人们最关注的夜间社会服务之一，近年来，各地相关行政管理机构也陆续出台相关扶持政策，鼓励商家上线夜间送药平台、发展24小时药店，提供夜间送药服务，推动解决“夜间买药难”问题。近日，iiMedia Research(艾媒咨询)最新发布《2021年中国夜间用药年度观察报告》，基于2021年初至2021年末的监测数据，对中国夜间用药市场持续追踪。报告显示，年初有61.2%的用户夜间生病选择忍，而年底这一数字降至52.1%，据推算年末夜间用药受益群体新增约4000万人。报告指出，日渐成熟的中国外卖送药平台，成为解决夜间用药的重要参与者。通过一年的发展，在美团买药“小黄灯”计划等24小时药店惠民工程的推动下，线上24小时药店数量增加、夜间买药配送速度更快、服务保障更加成熟，用户知晓度有了较大提升，夜间买药难的问题得到有效缓解。
Among many social services，night medication has become one of the night social services that people pay most attention to. In recent years，relevant administrative agencies around the country have also successively issued relevant support policies to encourage businesses to launch night medication delivery platforms，develop 24-hour pharmacies，provide night medication delivery services， and promote the solution of the problem of "difficulty in buying drugs at night". Recently， iiMedia Research released the annual observation report on nighttime medication in China in 2021，which continuously tracks China's nighttime medication market based on the monitoring data from the beginning of 2021 to the end of 2021. The report shows that at the beginning of the year， 61.2% of users chose to tolerate illness at night，while at the end of the year，the figure fell to 52.1%. It is estimated that about 40 million people will benefit from night medication at the end of the year.The report points out that the increasingly mature Chinese takeout delivery platform has become an important participant in solving the problem of night medication. Through one year's development，driven by the 24-hour pharmacy benefit project such as the "small yellow light" plan of meituan drug purchase， the number of online 24-hour pharmacies has increased，the speed of drug purchase and distribution at night is faster，the service guarantee is more mature，the user awareness has been greatly improved，and the problem of difficult drug purchase at night has been effectively alleviated.
- 1
- 2
- 3
- 4
- 5
- 6
- 27
